SpyBiotech Ltd, whose vaccine platform binds antigens to vaccine delivery platforms, has appointed Prakash Bhuyan as chief medical officer. Dr Bhuyan is an infectious disease specialist who was most recently CMO at Aerium and earlier head of clinical development for vaccines and immune therapies at AstraZeneca. He also led product development of an HPV therapeutic into Phase 3 while serving as senior vice president, clinical development, at Inovio Pharmaceuticals. Dr Bhuyan has an MD and PhD in immunology from the University of Texas Southwestern Medical Center, US. SpyBiotech, a spin-out of the University of Oxford, UK, has research collaboration with the university and its vaccine candidate against human cytomegalovirus (HCMV) is in a UK Phase 1 trial.
SpyBiotech announced the appointment on 12 August 2024.
Copyright 2024 Evernow Publishing Ltd.